Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2.
about
Identification of potential conserved RNA secondary structure throughout influenza A coding regionsStructure based approaches for targeting non-coding RNAs with small moleculesTargeting the androgen receptor with steroid conjugatesNMR spectroscopy and molecular dynamics simulation of r(CCGCUGCGG)₂ reveal a dynamic UU internal loop found in myotonic dystrophy type 1.A Crystal Structure of a Model of the Repeating r(CGG) Transcript Found in Fragile X SyndromeMyotonic Dystrophy Type 1 RNA Crystal Structures Reveal Heterogeneous 1 × 1 Nucleotide UU Internal Loop ConformationsDesign of a bioactive small molecule that targets r(AUUCU) repeats in spinocerebellar ataxia 10Approaches to Validate and Manipulate RNA Targets with Small Molecules in CellsCharacterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNATherapeutics development in myotonic dystrophy type 1.Examining the interactions of the splicing factor MBNL1 with target RNA sequences via a label-free, multiplex methodStructure of the myotonic dystrophy type 2 RNA and designed small molecules that reduce toxicity.Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3.Two-dimensional combinatorial screening and the RNA Privileged Space Predictor program efficiently identify aminoglycoside-RNA hairpin loop interactionsTwo-dimensional combinatorial screening of a bacterial rRNA A-site-like motif library: defining privileged asymmetric internal loops that bind aminoglycosides.Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophyMethods to enable the design of bioactive small molecules targeting RNA.The role of flexibility in the rational design of modularly assembled ligands targeting the RNAs that cause the myotonic dystrophiesOligonucleotide-based strategies to combat polyglutamine diseases.Defining the RNA internal loops preferred by benzimidazole derivatives via 2D combinatorial screening and computational analysisReducing levels of toxic RNA with small moleculesNew trends in aminoglycosides use.Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcriptsRationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive.MBNL proteins and their target RNAs, interaction and splicing regulation.Probing a 2-aminobenzimidazole library for binding to RNA internal loops via two-dimensional combinatorial screening.Identifying the preferred RNA motifs and chemotypes that interact by probing millions of combinations.Structure-activity relationships through sequencing (StARTS) defines optimal and suboptimal RNA motif targets for small moleculesDefining RNA motif-aminoglycoside interactions via two-dimensional combinatorial screening and structure-activity relationships through sequencing.Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.Targeting folded RNA: a branched peptide boronic acid that binds to a large surface area of HIV-1 RRE RNAFeatures of modularly assembled compounds that impart bioactivity against an RNA target.Molecular recognition of 6'-N-5-hexynoate kanamycin A and RNA 1x1 internal loops containing CA mismatches.Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1.Small molecules that target the toxic RNA in myotonic dystrophy type 2.Influencing uptake and localization of aminoglycoside-functionalized peptoids.A dynamic combinatorial approach for identifying side groups that stabilize DNA-templated supramolecular self-assemblies.Selective inhibition of MBNL1-CCUG interaction by small molecules toward potential therapeutic agents for myotonic dystrophy type 2 (DM2)HIV-1 drug discovery: targeting folded RNA structures with branched peptides.RNA Structures as Mediators of Neurological Diseases and as Drug Targets.
P2860
Q24633659-FF0977EE-0535-4479-8BE9-BC6987FD17C4Q26858823-EC2133B5-9398-4F5D-B3A0-2157AA847D81Q26995692-6E332152-D30E-4ED8-A308-3F782298637EQ27666465-35DA7795-E724-40B2-8CA6-DDBE9120901BQ27670857-C613604E-7498-4DEE-A0E6-6DFE304FABF5Q27674953-264CE8D1-4A00-4246-B321-7CCB0B989F10Q28828843-DB0CB1A2-7985-4060-B7B5-8D4EE5C4AFC9Q28833658-83E04BA7-0723-455A-B262-DBD0912B1567Q30276963-89E2ABB1-29AD-42A4-A7FD-EC61E78E30E3Q30425796-9E212B1E-F46B-496C-B2E0-A86E06AC7397Q30572364-FBDE1CE4-35E6-40FC-8073-92BF9C45700EQ30573524-E6D10734-1BF2-42C2-9E8B-58529A534B9AQ33474085-814032A5-22A3-4390-A31D-758BEA9A7D2AQ33499621-02A7219E-C907-4DAF-ADAE-8065112569F8Q33527092-626240AB-567D-4BC9-BA7B-E7DE747A29BDQ33569231-C1A605D1-AC8B-4341-AB5B-76B9FF762264Q33609375-296E020C-A43F-4E0C-85D0-8A08BB5D1DEFQ33763698-6291680A-C9FF-46B2-BAB1-B4B3690C377BQ33791247-E4E1FDD4-7E2C-4426-BF5B-6A5663A029FAQ33908985-F5BB8966-9FF8-49CF-88DC-3859769E8DEDQ33939836-04094CF7-75A8-4054-ABAF-1EBA61FDAC13Q33951177-FFD52EF3-7068-49A1-8B64-F08DF193E4BAQ34129996-AD705D4F-D147-4E14-8593-88E3AF904708Q34158462-293135A0-9FB0-4DAB-8107-922D367A0E8AQ34248811-85F6F3DC-C7D7-41B3-8E03-F2EEDA1EE7EDQ34408537-CFED70D6-2910-444D-8A5C-B2FBE1118407Q34437297-1D61725A-53E5-48F9-A5D5-9DB9D2D7DA15Q34494796-690F710A-28E7-45E2-B887-B325A598D919Q34747084-DB32C125-4EC3-4DB6-AB7F-CFE007CD241BQ34786164-4A471675-51A0-4A8D-AF8B-6CB2106D7816Q34909697-8F7E0ABE-0BD5-40D8-9399-88E075AEF77CQ34986416-B40E4B77-142D-4271-8654-7B182E8DDCB2Q35020416-4EA5F6FD-87B4-49FC-8974-432468730710Q35031314-F53DF84B-806D-46B1-98B4-A8661509C9D4Q35061734-B76D40A2-D2E0-4485-ADB5-4A7A6651DEE6Q35103346-084155FF-8AF5-4E6C-912D-A240FA013D5AQ35139112-B3448BF6-BFCE-42C3-A5B5-9C5D3BBB73CEQ35468472-A706F045-C71E-4274-BD4C-0969D6F93DE5Q35626292-D845D47C-31F0-4BCF-AF79-1AE2BB0FC489Q35868044-54E6F285-8FBD-47B6-A390-D8134DFD6A74
P2860
Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Rational and modular design of ...... t causes myotonic dystrophy 2.
@ast
Rational and modular design of ...... t causes myotonic dystrophy 2.
@en
type
label
Rational and modular design of ...... t causes myotonic dystrophy 2.
@ast
Rational and modular design of ...... t causes myotonic dystrophy 2.
@en
prefLabel
Rational and modular design of ...... t causes myotonic dystrophy 2.
@ast
Rational and modular design of ...... t causes myotonic dystrophy 2.
@en
P2093
P2860
P356
P1433
P1476
Rational and modular design of ...... t causes myotonic dystrophy 2.
@en
P2093
Alexei Pushechnikov
Matthew D Disney
Melissa M Lee
P2860
P304
P356
10.1021/CB900025W
P577
2009-05-01T00:00:00Z